Contact: Kathryn Ruehle, 914-740-2100, email@example.com
ATTD Names Diabetes Technology & Therapeutics Its Official Journal
New Rochelle, NY, February 6, 2014—The prestigious Advanced Technologies & Treatments for Diabetes (ATTD) Conference has selected Diabetes Technology & Therapeutics (DTT), edited by Satish Garg, MD and published by Mary Ann Liebert, Inc., publishers, as its official journal. ATTD and DTT both represent the leading conference and journal, respectively, in the field of new technologies and treatments for diabetes. The Journal is available in 170 countries around the world.
DTT and ATTD have been working together for several years on the annual ATTD Yearbook which covers the leading topics and controversies in the field of diabetes and is authored by key international opinion leaders in their area of expertise. The Journal has also released the abstracts for the ATTD 2014 meeting—the 7th International Conference on Advanced Technologies & Treatments for Diabetes—which opened yesterday in Vienna, Austria and continues through February 8.
ATTD 2014 is Chaired by Moshe Phillip, MD, Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel and Vice Dean for Research and Development at Sackler Faculty of Medicine, Tel-Aviv University, and Tadej Battelino, MD, Department of Endocrinology, Diabetes & Metabolism, University Medical Center, University Children’s Hospital, Ljubljana, Slovenia.
The International Conference on Advanced Technologies & Treatments for Diabetes presents top-caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.